A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

These data indicate that p53 has a determining role in allowing adenovirus to induce CPE and probably, therefore, in virus replication. Moreover, although the E1b58kDa protein is not required for ...